Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells 7,379 Shares of Stock

UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

UroGen Pharma Trading Up 0.8 %

URGN opened at $11.30 on Wednesday. The company has a fifty day moving average of $11.12 and a two-hundred day moving average of $12.64. UroGen Pharma Ltd. has a fifty-two week low of $9.78 and a fifty-two week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the prior year, the firm earned ($0.68) EPS. As a group, analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Institutional Trading of UroGen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC lifted its position in shares of UroGen Pharma by 15.2% during the 4th quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock valued at $1,493,000 after buying an additional 18,514 shares in the last quarter. Bank of New York Mellon Corp raised its position in UroGen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after acquiring an additional 6,430 shares during the period. Rhumbline Advisers lifted its holdings in UroGen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after purchasing an additional 1,402 shares in the last quarter. SG Americas Securities LLC grew its position in shares of UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after purchasing an additional 6,207 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after purchasing an additional 49,318 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on URGN. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, January 23rd. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.